Halozyme Therapeutics - Stock Price History | HALO

Historical daily share price chart and data for Halozyme Therapeutics since 2021 adjusted for splits. The latest closing stock price for Halozyme Therapeutics as of September 27, 2021 is 40.15.
  • The all-time high Halozyme Therapeutics stock closing price was 51.45 on February 24, 2021.
  • The Halozyme Therapeutics 52-week high stock price is 56.40, which is 40.5% above the current share price.
  • The Halozyme Therapeutics 52-week low stock price is 25.70, which is 36% below the current share price.
  • The average Halozyme Therapeutics stock price for the last 52 weeks is 41.83.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Halozyme Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 26.4060 18.1000 43.6200 13.9000 42.7100 140.89%
2019 16.5376 14.8000 19.5300 13.9400 17.7300 21.19%
2018 17.9282 20.2000 21.2000 13.3300 14.6300 -27.79%
2017 14.4885 9.9900 20.8000 9.9900 20.2600 105.06%
2016 10.1175 16.6400 16.6400 7.1700 9.8800 -42.99%
2015 17.0320 9.8200 24.7500 9.8200 17.3300 79.59%
2014 10.3892 15.0100 17.5700 7.0900 9.6500 -35.62%
2013 8.5436 6.7900 15.7000 5.1100 14.9900 123.40%
2012 8.2188 9.5400 13.3500 4.3000 6.7100 -29.44%
2011 7.0963 7.9000 9.7300 5.6200 9.5100 20.08%
2010 7.2231 6.1100 9.0200 5.4000 7.9200 34.92%
2009 6.3992 5.8500 7.8900 4.1000 5.8700 4.82%
2008 5.8338 6.7800 8.2400 2.7700 5.6000 -21.24%
2007 8.7771 8.1000 10.7600 6.1000 7.1100 -11.68%
2006 2.9132 1.8800 8.2500 1.8100 8.0500 342.31%
2005 1.8457 2.0700 2.2000 1.6000 1.8200 -17.27%
2004 2.9122 4.2500 4.6300 1.4300 2.2000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.715B $0.268B
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29